Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.
Recce Pharmaceuticals Ltd announced the dispatch of documents related to its 2025 Annual General Meeting to shareholders. The company’s innovative anti-infective solutions, which have garnered significant recognition, position it as a key player in addressing global health challenges related to antibiotic resistance. The upcoming meeting is set to discuss these advancements and their implications for stakeholders.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company focused on developing a new class of synthetic anti-infectives aimed at tackling antibiotic-resistant superbugs. Their product pipeline includes patented, broad-spectrum synthetic polymer anti-infectives such as RECCE 327 for serious bacterial infections, RECCE 435 for oral bacterial infections, and RECCE 529 for viral infections. The company has received recognition from the World Health Organization and the FDA for its efforts in combating antimicrobial resistance.
Average Trading Volume: 113,899
Technical Sentiment Signal: Hold
Current Market Cap: A$120M
See more data about RCE stock on TipRanks’ Stock Analysis page.